gp120w61d

gp120w61d is a recombinant form of the HIV-1 envelope glycoprotein gp120, specifically derived from the W61D strain. It is primarily used as an investigational vaccine component to induce immune responses against HIV-1. The mechanism of action involves acting as an antigen to stimulate both humoral and cellular immunity, targeting the HIV envelope protein gp120. This approach aims to generate neutralizing antibodies and T cell responses that could potentially prevent or control HIV infection[1][8]. The National Institute of Allergy & Infectious Diseases (NIAID) has been involved in its development for use in combination vaccines and clinical trials evaluating safety and immunogenicity[1][6].